Interview: Altan Eyes Opportunities In US Pain Market
Executive Summary
The Irish specialty pharma has made its first filing in the US with an infusion of acetaminophen that Altan hopes will break the monopoly of Mallinckrodt's Ofirmev.
You may also be interested in...
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
C4XD Delisting Highlights Funding Frustration For UK Biotechs
The Manchester-based group has had enough of being undervalued in the public markets and is going private again.
Novo Reaches Winning Post With Gamechanger Once-Weekly Insulin
The Danish drugmaker is cementing its leadership in diabetes with an imminent approval in Europe for Awiqli which reduces the number of basal insulin injections for patients from seven to just one per week.